| Muhammad Mahdi Nashatizadeh, MD | |
|
10550 Quivira Rd, Suite 530, Overland Park, KS 66215-2306 | |
| (913) 599-3828 | |
| (913) 599-3451 |
| Full Name | Muhammad Mahdi Nashatizadeh |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 21 Years |
| Location | 10550 Quivira Rd, Overland Park, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083730501 | NPI | - | NPPES |
| 1083730501 | Medicaid | MO | |
| 200623770A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 04-06020 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.
In an outbreak of Legionnaires' disease, finding the exact source as quickly as possible is essential to preventing further infections. To date, a standard analysis takes days. Researchers at the Technical University of Munich have now developed a rapid test that achieves the same result in about 35 minutes.
Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.
› Verified 3 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.
In an outbreak of Legionnaires' disease, finding the exact source as quickly as possible is essential to preventing further infections. To date, a standard analysis takes days. Researchers at the Technical University of Munich have now developed a rapid test that achieves the same result in about 35 minutes.
Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Muhammad Mahdi Nashatizadeh, MD 10550 Quivira Rd, Suite 530, Overland Park, KS 66215-2306 Ph: (913) 599-3828 | Muhammad Mahdi Nashatizadeh, MD 10550 Quivira Rd, Suite 530, Overland Park, KS 66215-2306 Ph: (913) 599-3828 |
News Archive
BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.
In an outbreak of Legionnaires' disease, finding the exact source as quickly as possible is essential to preventing further infections. To date, a standard analysis takes days. Researchers at the Technical University of Munich have now developed a rapid test that achieves the same result in about 35 minutes.
Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.
› Verified 3 days ago
Anne S. Clark, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10500 Barkley St Ste 220, Overland Park, KS 66212 Phone: 913-738-9235 Fax: 913-738-9285 | |
Stacy Dawn Younger, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12140 Nall Ave, Suite 230, Overland Park, KS 66209 Phone: 913-661-9434 Fax: 913-661-4688 | |
Dr. Beverley Faye James, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9101 W 73rd St Apt 206, Overland Park, KS 66204 Phone: 913-262-6161 | |
Ian Leslie Belson, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12140 Nall, Suite 230, Overland Park, KS 66209 Phone: 913-661-9434 Fax: 913-661-4688 | |
Dr. Bernard Mark Abrams, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5520 College Boulevard, Suite 320, Overland Park, KS 66211 Phone: 816-322-4834 Fax: 816-322-2005 | |
Dr. Joan Mollman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5347 W 100th Ter, Overland Park, KS 66207 Phone: 610-864-8338 |